Dr Teagan Brown


Contact via email

Gut viruses & viromics


I am a microbiologist, specialising in bacteriophages (viruses of bacteria)

My research career began at the Institute for Molecular Science, La Trobe University (Australia). During my PhD I isolated and characterised bacteriophages for a range of bacterial pathogens, including Cutibacterium (formerly Propionibacterium) acnes, which is important in the development of the skin condition acne. These bacteriophages were then formulated into a cream which has the potential to be used on the skin. I also investigated how bacteriophages could be delivered to the various other sites of infection, by formulating bacteriophages into semi-solid and solid dosage forms. As antibiotic resistance globally spreads, bacteriophages and their formulations could become an important tool for therapy.

With collaborators at the Melbourne Dental School (University of Melbourne, Australia) and the Royal Melbourne Hospital (Australia), my post-doctoral research focused on other clinical bacteria involved with the oral cavity and periodontal disease. As well as the expression of bacteriophage proteins which may be useful anti-bacterial agents.

For my current post-doctoral position, I joined the Quadram Institute in July 2019 where I am investigating the role of viruses within the human gut and mechanisms we can use to control bacteria.

Key Publications

Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J (2016) The Formulation of Bacteriophage in a Semi Solid Preparation for Control of Propionibacterium acnes Growth. PLoS ONE 11(3): e0151184. https://doi.org/10.1371/journal.pone.0151184

Brown, T. L., Thomas, T., Odgers, J. , Petrovski, S. , Spark, M. J. and Tucci, J. (2017), Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria. J Pharm Pharmacol, 69: 244-253. doi:10.1111/jphp.12673

Brown TL, Petrovski S, Hoyle D, Chan HT, Lock P, Tucci J (2017) Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca. PLoS ONE 12(8): e0183510. https://doi.org/10.1371/journal.pone.0183510

Brown, T. L., S. Petrovski, H. T. Chan, M. J. Angove and J. Tucci (2018). “Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia.” Pharmaceuticals (Basel) 11(1). https://doi.org/10.3390/ph11010026

Kabwe, M., T. L. Brown, S. Dashper, L. Speirs, H. Ku, S. Petrovski, H. T. Chan, P. Lock and J. Tucci (2019). Genomic, morphological and functional characterisation of novel bacteriophage FNU1 capable of disrupting Fusobacterium nucleatum biofilms. Sci Rep 9(1): 9107.
DOI: 10.1038/s41598-019-45549-6

Related News